Robert W. Baird Issues Positive Forecast for Castle Biosciences (NASDAQ:CSTL) Stock Price

Castle Biosciences (NASDAQ:CSTL) had its price objective upped by equities research analysts at Robert W. Baird from $41.00 to $44.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price suggests a potential upside of 38.02% from the stock’s previous close.

A number of other analysts have also recently commented on CSTL. BTIG Research boosted their price target on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. KeyCorp reiterated an “overweight” rating and set a $50.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 29th. Zacks Research raised Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, February 2nd. Lake Street Capital upped their price target on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Canaccord Genuity Group increased their price objective on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.57.

Castle Biosciences Stock Up 3.4%

NASDAQ:CSTL opened at $31.88 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. The firm’s 50-day moving average price is $37.37 and its 200-day moving average price is $31.06. The company has a market capitalization of $930.58 million, a PE ratio of -70.84 and a beta of 1.06. Castle Biosciences has a 1-year low of $14.59 and a 1-year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.15. The business had revenue of $81.88 million for the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. On average, equities analysts predict that Castle Biosciences will post 0.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Derek J. Maetzold sold 4,017 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the sale, the insider directly owned 87,715 shares of the company’s stock, valued at $3,509,477.15. This trade represents a 4.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Kristen M. Oelschlager sold 14,888 shares of Castle Biosciences stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total value of $585,247.28. Following the completion of the sale, the chief operating officer owned 12,323 shares of the company’s stock, valued at $484,417.13. The trade was a 54.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 29,617 shares of company stock worth $1,167,887. Corporate insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Amundi grew its position in Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after purchasing an additional 4,111 shares during the period. AQR Capital Management LLC boosted its stake in shares of Castle Biosciences by 548.9% in the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares during the period. Jones Financial Companies Lllp increased its position in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in Castle Biosciences by 1.0% in the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock valued at $1,439,000 after acquiring an additional 707 shares during the period. Institutional investors own 92.60% of the company’s stock.

Key Headlines Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Quarterly results surprised to the upside: Q4 EPS was -$0.08 vs. consensus -$0.23 and quarterly revenue modestly beat estimates, supporting near-term momentum. Read More.
• Positive Sentiment: Full-year revenue topped guidance — FY2025 revenue $344M (vs. guidance) and core test reports (DecisionDx‑Melanoma, TissueCypher) rose ~37%, signaling durable demand for core diagnostics. Read More.
• Positive Sentiment: Management set 2026 revenue guidance of $340–$350M, above consensus (~$335M), and highlighted the limited launch of AdvanceAD‑Tx (new dermatology test) as a material TAM expansion driver. That outlook is a clear near-term growth catalyst. Read More.
• Positive Sentiment: Healthy balance sheet and margins: cash + marketable securities ~ $299.5M and adjusted gross margins remain strong (~80% adjusted), giving the company runway to commercialize new tests. Read More.
• Neutral Sentiment: Management commentary and full call transcript are available for additional context on commercialization plans and assumptions behind guidance. Investors can review the earnings call transcript and slides to vet execution risk. Read More.
• Neutral Sentiment: Street reception: analysts show a generally constructive stance (average rating ~“Moderate Buy” and several buy/outperform ratings and price targets above current levels), which can support follow-through. Read More.
• Negative Sentiment: Profitability erosion: GAAP net loss widened to $24.2M in 2025 (adjusted EBITDA declined to $44M from $75M in 2024). Investors should weigh revenue growth against falling profitability and higher non‑cash/amortization charges. Read More.
• Negative Sentiment: Operational headwinds: the company discontinued IDgenetix and experienced a Medicare coverage change for DecisionDx‑SCC that reduced revenue in that segment — these items depressed some topline components in 2025. Read More.
• Negative Sentiment: Insider selling flagged by data aggregators (noted recent multiple insider sales), which can create investor concern about near-term share supply and sentiment — monitor filings for detail. Read More.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.